<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02676349</url>
  </required_header>
  <id_info>
    <org_study_id>2014-005681-29</org_study_id>
    <nct_id>NCT02676349</nct_id>
  </id_info>
  <brief_title>Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)</brief_title>
  <official_title>Two Arm, Prospective, Multicenter Randomized Phase II Trial of Neoadjuvant Modified Folfirinox Regimen, With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized phase II trial. The aim of this study is to assess the&#xD;
      efficacy of two therapeutics strategies. Patients with borderline-resectable pancreatic&#xD;
      cancer (BRPC) will be randomly in two arms : neoadjuvant mFolfirinox followed with or without&#xD;
      preoperative chemoradiotherapy with capecitabine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgery, especially if followed by adjuvant chemotherapy, offers the only chance of cure of&#xD;
      pancreatic cancer. At first diagnosis, after careful assessment, only 10 to 15% of patients&#xD;
      are considered to be candidates for surgical resection and about 7% have a potentially&#xD;
      resectable disease. These potentially resectable tumors called &quot;borderline resectable&#xD;
      pancreatic cancer&quot; (BRPC) are conceptualized as those that involve the mesenteric vasculature&#xD;
      to a limited extent and those for which resection, while possible, would likely be&#xD;
      compromised by positive surgical margins (R1) in the absence of neoadjuvant treatment. R0&#xD;
      resection is indeed considered as an independent prognostic factor for survival when the&#xD;
      surgical procedures, histological examination and definition of microscopic invasion are&#xD;
      standardized.&#xD;
&#xD;
      The objectives of neoadjuvant treatments of BRPC is to reduce tumor volume before surgery in&#xD;
      order to improve the chances of radical (R0) resection and to reduce the rate of lymph node&#xD;
      positivity and recurrences. The primary outcome in published studies is usually R0 resection&#xD;
      rate, but these results also depend on the number of margins examined and the definition of&#xD;
      microscopic margin involvement. Prospective studies with consistent selection criteria and&#xD;
      standardized assessment criteria are needed.&#xD;
&#xD;
      Different neoadjuvant therapeutic strategies have been tested in pilot studies: preoperative&#xD;
      chemoradiotherapy or neoadjuvant chemotherapy, followed or not by a preoperative&#xD;
      (chemo)radiotherapy. Due to the lack of randomized studies, the best sequence of treatment&#xD;
      administration has not been established.&#xD;
&#xD;
      The aim of this prospective, randomized, multicenter, trial is to evaluate the R0 resection&#xD;
      rate with neoadjuvant Folfirinox, followed or not by radiochemotherapy for patients with&#xD;
      borderline resectable pancreatic cancers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2016</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of two neoadjuvant therapies in patients with borderline resectable pancreatic carcinoma evaluated on histological R0 resection margin rate</measure>
    <time_frame>up to 7.5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the toxicities associated with chemotherapy and chemoradiotherapy</measure>
    <time_frame>up to 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the proportion of resected patients</measure>
    <time_frame>up to 7.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the response rate to chemotherapy and chemoradiotherapy</measure>
    <time_frame>up to 7.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the histological complete response rate in resected patients.</measure>
    <time_frame>up to 7.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the perioperative mortality rate</measure>
    <time_frame>up to 8.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the perioperative morbidity rate</measure>
    <time_frame>up to 8.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the overall survival</measure>
    <time_frame>up to 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the quality of life</measure>
    <time_frame>up to 7.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the loco-regional relapse-free survival</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the metastatic Progression Free Survival</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the progression-free survival</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy with mFolfirinox regimen + concomitant chemoradiotherapy + surgery + adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant chemotherapy with mFolfirinox regimen + surgery + adjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFolfirinox</intervention_name>
    <description>oxaliplatin folinic acid irinotecan 5FU oxaliplatin</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chemoradiotherapy</intervention_name>
    <description>conformational external irradiation (50.4 Gy) + capecitabine</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <description>1 to 4 weeks after neoadjuvant treatment according to tumour response</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant chemotherapy</intervention_name>
    <description>Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Adult patients ≥ 18 years and ≤ 75 years of age&#xD;
&#xD;
          -  Histologic or cytologic proven adenocarcinoma of the pancreas (histologic confirmation&#xD;
             of diagnosis is preferred)&#xD;
&#xD;
          -  Confirmation by independent multidisciplinary expert review of borderline resectable&#xD;
             status, according to NCCN-Clinical Practice Guidelines in Oncology &quot;pancreatic&#xD;
             adenocarcinoma&quot;, version 1.2015.&#xD;
&#xD;
          -  Adequate hematologic function, as follows:&#xD;
&#xD;
          -  absolute neutrophil count (ANC) ≥ &gt; 2000/mm3&#xD;
&#xD;
          -  platelet count ≥ 100 000/mm3&#xD;
&#xD;
          -  haemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Adequate renal, hepatic and bone marrow function, defined as:&#xD;
&#xD;
               -  Calculated creatinine clearance ≥ 50 mL/min according to MDRD formula&#xD;
&#xD;
               -  Serum total bilirubin ≤ 1.5 times the institutional upper limit of normal.&#xD;
                  Patients with a biliary short metal stent due to cancer obstruction may be&#xD;
                  included provided that high-quality imaging is performed before stenting and&#xD;
                  bilirubin level after stent insertion decreased to ≤ 20 mg/L (≤ 34 µmol/l), and&#xD;
                  there is no cholangitis.&#xD;
&#xD;
          -  Male and female subjects who agree to use highly effective methods of birth control&#xD;
             (e.g., condoms, combined oral contraceptives, some intrauterine devices [IUDs], sexual&#xD;
             abstinence, or sterilized partner)&#xD;
&#xD;
               -  for male subject: during the treatment and for up to 6 months after the last dose&#xD;
                  of oxaliplatin or up to 3 months after the last dose of irinotcan.&#xD;
&#xD;
               -  for female subject: during the treatment and for up to 4 months after the last&#xD;
                  dose of oxaliplatin or up to 3 months after the last dose of irinotcan.&#xD;
&#xD;
          -  Ability to provide written informed consent before the start of any study specific&#xD;
             procedures&#xD;
&#xD;
          -  Patient's legal capacity to consent to study participation and to understand and&#xD;
             comply with the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previous treatment of the pancreatic cancer except biliary short metal stenting&#xD;
             (chemotherapy, targeted tumor therapy, local ablative therapy, previous irradiation&#xD;
             within the actual fields of planned radiotherapy)&#xD;
&#xD;
          -  Evidence of distant metastases including ascites&#xD;
&#xD;
          -  Evidence of extent of pancreatic cancer beyond that defined as &quot;borderline resectable&quot;&#xD;
             : suspicious lymphadenopathy outside of the standard field of resection (i.e.,&#xD;
             aortocaval nodes, distant abdominal nodes)&#xD;
&#xD;
          -  Contraindication for pancreas resection&#xD;
&#xD;
          -  Pregnant or breast feeding females&#xD;
&#xD;
          -  Patients with known Gilbert's Syndrome or homozygosity for UGT1A1*28 polymorphism&#xD;
&#xD;
          -  Participation in any other clinical trial or treatment with any experimental drug&#xD;
             within 28 days before enrolment to the study or during study participation until the&#xD;
             end of treatment visit that can be interfering with the objectives of the study&#xD;
&#xD;
          -  Previous or concurrent malignant tumor disease other than underlying tumor disease&#xD;
             (with the exception of cervical cancer in situ, adequately treated non-melanoma skin&#xD;
             cancers, superficial bladder tumors (Ta, Tis, and T1) or any curatively treated&#xD;
             without chemotherapy and favourable prognosis tumors without evidence of disease for &gt;&#xD;
             3 years prior to enrolment)&#xD;
&#xD;
          -  Any severe and/or uncontrolled medical conditions including but not limited to:&#xD;
&#xD;
               -  Clinically significant cardiovascular or vascular disease : angina pectoris (even&#xD;
                  controlled), previous myocardial infarction, serious uncontrolled cardiac&#xD;
                  arrhythmia, chronic heart failure, acute or chronic infectious disease requiring&#xD;
                  general treatment)&#xD;
&#xD;
               -  Acute and chronic, active infectious disorders that requires systemic treatment&#xD;
                  --- Peripheral polyneuropathy &gt; grade 1&#xD;
&#xD;
               -  Any previous inflammatory disease of colon or rectum&#xD;
&#xD;
               -  Any other severe concomitant disease or disorder, which could influence patient's&#xD;
                  ability to participate in the study and his/her safety during the study e.g.&#xD;
                  severe hepatic, renal, pulmonary, metabolic, or psychiatric disorders&#xD;
&#xD;
          -  Hypersensitivity against any of the study drugs (gemcitabine, oxaliplatin, irinotecan,&#xD;
             5-fluorouracil, folinic acid), or the ingredients of these drugs (e.g. fructose).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry CONROY, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Baptiste BACHET, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Groupe Hospitalier Pitié-Salpêtrière</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal HAMMEL, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Beaujon Assistance Publique - Hôpitaux de Paris (AP-HP)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jen Louis MERLIN, Md PharmaD</last_name>
    <phone>03 83 59 83 07</phone>
    <email>jl.merlin@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurinda FERNANDES</last_name>
    <phone>03 83 59 84 87</phone>
    <email>l.fernandes@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BECHADE Dominique, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LECAILLE Cédric, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Morvan</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>METGES Jean-Philippe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HAMMEL Pascal, PR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Colmar</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Breysacher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor (APHP)</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BAUMGAERTNER Isabelle, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Bicêtre (APHP)</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>THIROT-BIDAULT Anne, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Mirabel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chru Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PIESSEN Guillaume, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infirmerie Protestante de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TAVAN David, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital européen Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RINALDI Yves, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DAHAN Laëtitia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli CALMETTES</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DELPERO Jean-Robert, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PORTALES Fabienne, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas REGENET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin (APHP)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CORIAT Romain, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LOUVET Christophe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pitié Salpêtrière (APHP)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BACHET Jean-Baptiste, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VENDRELY Véronique, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BOUCHE Olivier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SULPICE Laurent, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SCHWARZ Lillian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHP Saint Grégoire</name>
      <address>
        <city>Saint Grégoire</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MIGLIANO Laurent, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>THIBAUDEAU Emilie, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chru Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LECOMTE Thierry, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chru Nancy</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AYAV Ahmet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CONROY Thierry, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2016</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mFolfirinox</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Neoadjuvant treatment</keyword>
  <keyword>Borderline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

